Please assess the completion status of the following clinical trial:

Trial Title: Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ages 18 or older.~* Clinical features of HD AND confirmatory family history of HD; OR Clinical features of HD AND CAG repeat expansion greater or equal to 36.~* Stage I or II of illness (TFC greater or equal to 7).~* Ambulatory and not requiring skilled nursing care at the time of enrollment.~* Must be capable of providing informed consent and complying with trial procedures.~* Additional inclusion criteria apply.~Exclusion Criteria:~* History of known sensitivity or intolerability to creatine monohydrate.~* Exposure to any investigational drug within 30 days of randomization (Baseline visit).~* Use of supplemental creatine at a dose greater than 10 grams within 30 days of randomization (Baseline visit).~* Screening laboratory abnormalities that in the judgment of the investigator would jeopardize safe conduct of study.~* Clinical evidence of unstable medical illness.~* Clinical evidence of unstable psychiatric illness.~* Additional exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Randomized to receive creatine monohydrate (up to 40 grams daily)
- B (Type: PLACEBO_COMPARATOR): Randomized to receive placebo (up to 40 grams daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).